ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...6566676869707172737475...129130»
  • ||||||||||  Review, Journal:  Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside. (Pubmed Central) -  Sep 15, 2021   
    Notably among the 109 overviewed inhibitors include quercetin, eriodictyol, baicalin, luteolin, melatonin, resveratrol and berberine from natural products, GC373, NP164 and HR2P-M2 from peptides, 5F9, m336 and MERS-GD27 from specific human antibodies, imatinib, remdesivir, ivermectin, chloroquine, hydroxychloroquine, nafamostat, interferon-β and HCQ from repurposing libraries, some iron chelators and traditional medicines. This review represents a model for further translational studies for effective anti-CoV therapeutic designs.
  • ||||||||||  ivermectin oral / Generic mfg.
    Retrospective data, Journal:  Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study. (Pubmed Central) -  Sep 14, 2021   
    A Statistical Package for Social Sciences (SPSS) Propensity Score Matching procedure was applied in a 1:1 ratio to homogeneously evaluate 271 healthcare personnel that adhered to a PrEP program with ivermectin at a weekly oral (PO) dose of 0.2 mg/kg, and 271 healthcare personnel who did not adhere to the program were assigned as a control group. In 28 days of follow-up, significant protection of ivermectin preventing the infection from SARS-CoV-2 was observed: 1.8% compared to those who did not take it (6.6%; p-value = 0.006), with a risk reduction of 74% (HR 0.26, 95% CI [0.10,0.71]).   These results suggest that compassionate use of weekly ivermectin could be an option as a preventive method in healthcare workers and as an adjunct to immunizations, while further well-designed randomized controlled trials are developed to facilitate scientific consensus.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Journal:  Covid-19: Hospital may cease giving patient ivermectin, US court rules, as prescriptions soar. (Pubmed Central) -  Sep 12, 2021   
    In 28 days of follow-up, significant protection of ivermectin preventing the infection from SARS-CoV-2 was observed: 1.8% compared to those who did not take it (6.6%; p-value = 0.006), with a risk reduction of 74% (HR 0.26, 95% CI [0.10,0.71]).   These results suggest that compassionate use of weekly ivermectin could be an option as a preventive method in healthcare workers and as an adjunct to immunizations, while further well-designed randomized controlled trials are developed to facilitate scientific consensus. No abstract available
  • ||||||||||  chloroquine phosphate / Generic mfg., hydroxychloroquine / Generic mfg.
    Journal:  Green Composite Sensor for Monitoring Hydroxychloroquine in Different Water Matrix. (Pubmed Central) -  Sep 11, 2021   
    Recently, Coronavirus (COVID-19) treatment was authorized by national and international medical organizations by chloroquine and hydroxychloroquine in certain hospitalized patients...The effectiveness of the electrochemical sensor was tested in different water matrices (in synthetic and real) and lower HCQ concentrations were detected. When comparing electrochemical determinations and spectrophotometric measurements, no significant differences were observed (mean accuracy 3.0%), highlighting the potential use of this sensor in different environmental applications.